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Bloodstream Infections in Febrile Neutropenic Children
with Cancer
Renato Hikawa, A. Sérgio Petrilli, Janaina Goto,
Fabianne Carlesse, Maria Aparecida Aguiar, Alexandre Marra,
Carlos Alberto Pereira. Pediatric Department and Infectious
Disease Department, Pediatric Oncology Institute, Federal
University of São Paulo, São Paulo, Brazil
Background: The treatment of febrile neutropenia is an emergency
which is based on each Institution' s epidemiology.
Objective: To evaluate clinical and epidemiologic features of
bloodstream infections (BSI) and sensibility profile of main agents
and identifies risk factors related mortality.
Methods: All positive blood cultures from January 1st 2004 to 31st
December 2006 were evaluated retrospectively. Patients with can-
cer submitted to chemotherapy, younger than 21, with absolute
neutrophil (<500 cell/mm3) and fever were included. Patients sub-
mitted to bone marrow transplant and fever related to transfusion
reaction, were excluded. Statistical analysis was done by SPSS pro-
gram; p<0.05 was considered significant.
Results: Four hundred and two BSI were reported but only 153
episodes were analyzed; 55% were male, 76% were >3 years,
20% were in CTI, 57% had a CVC and 17% were submitted to
surgery. 95.6% were represented by bacteria, 4.4% were fungi.
Gram-negative rods caused 54.3%. Most common agents were:
Gram-negative E. coli (37%), K. pneumonie (15%) and Acineto-
bacter spp. (14%) and Gram-positive cocci were Coagulase Neg-
ative Staphylococci (40%), S. aureus (19%) S. viridans (17%). 77%
of Coagulase Negative Staphylococci were resistant to oxacilin
and 67% to clindamycin. All S. aureus were sensibly to oxacilin.
K. pneumoniae presented high resistant levels to cephalosporins
(38% to ceftriaxone, 43% to ceftazidime and 36% to cefepime)
and 43% were ESBL. Gram-negative rods (95 episodes) were ana-
lyzed together and were observed low resistance to polymyxinB
(0%) and to piperacillin/tazobactam (3%) against high resistance to
cephalosporins (17% to cefepime, 19% to ceftazidime and 22% to
ceftriaxone). The overall mortality rate within 30 days from the
first positive blood culture was 12.4%. Multivariate logistic regres-
sion demonstrated that presence of organic dysfunction (severe
sepsis and septic shock) and inappropriate initial antibiotic therapy
were independently associated to mortality (OR 9.42 and 11.46, re-
spectively).
Conclusions: Gram-negative bacteria presented high resistance to
antibiotics commonly used in our institution. The presence of or-
ganic dysfunction and inappropriate initial antibiotic therapy were
associated to mortality. Results confirm the importance of knowing
local epidemiology for the best treatment then reducing mortal-
ity.
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Emergence and Control of an Outbreak of Clostridium
difficile BI/NAP1/027 strain in a Comprehensive Cancer
Center
Karen Vigil1, Javier Adachi1,2,3, Zhi-Dong Jiang3,
Dhanesh Rathod2, Lisa Burton2, Jeffrey Tarrand2,
Herbert DuPont1,3, Issam Raad2, Roy Chemaly2. 1The University
of Texas Health Science Center at Houston, Medical School,
Houston, Texas; 2The University of Texas - M.D. Anderson Cancer
Center, Houston, Texas; 3The University of Texas Health Science
Center at Houston, School of Public Health, Houston, Texas
Background: Clostridium difficile infection (CDI) was considered a
mild nosocomial disease associated almost exclusively with the use
of antibiotics, but its epidemiology has changed dramatically.
Since 2002, outbreaks of severe CDI with a new strain BI/NAP1/027
have emerged and were associated with increased mortality and
reduced effectiveness of standard therapy. However, there is lack
of data about the epidemiology of this new virulent strain in cancer
centers.
Objective: To describe an outbreak of C. difficile BI/NAP 1/027
strain and the impact of multifaceted infection control measures.
Methods:We implemented in past years an active surveillance pro-
gram for CDI that allows us to collect and review the microbiology
records of all patients with positive C. difficile toxin in stools. As
part of this active surveillance, an outbreak was identified in May
of 2007. C. difficile isolates were cultured on cyloserine-cefoxitin-
fructose agar and polymerase chain reaction (PCR) was used to
identify the presence of binary toxin, a marker of the BI/NAP1/027
strain.
Results: During 2007, there were 321 cases of CDI with an average
rate of 0.86/1000 patient-days. Since March of 2007, we evidenced
an increase in the rate of CDI from 0.38 in February to 0.72 in March
with a peak rate of 1.92 in May of 2007 (p<0.05). An outbreak
team was convened and an action plan was developed. Mainly, ed-
ucation measures were implemented on floors and new signs were
placed on isolation carts reinforcing hand hygiene procedures with
the use of water of soap, environmental cleaning with 10% bleach,
and reinforcing the use of personnel protective equipment. As a
result, the rate of CDI decreased progressively to 0.44 in Novem-
ber 2007. Three clusters of patients with CDI, in different location
each, were identified during the outbreak necessitating additional
education and environmental cleaning in the affected areas. Since
May 2007, we were able to isolate 25 C. difficile strains from pa-
tients with CDI. Moreover, we have also confirmed for the first time
in our Institution the presence of C. difficile BI/NAP 1/027 binary
toxin in 6 cases.
Conclusion: We were able to confirm the change in the epidemi-
ology of CDI in our institution with the development of an out-
break secondary to the emergence of the new hypervirulent strain
BI/NAP1/027. Infection control measures were the cornerstone to
control this outbreak in this immunocompromised population.
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Clinical Characteristics and Virulence Factors of
Escherichia coli Pyomyositis: A New Entity in our Patients
with Hematologic Malignancies
Karen Vigil1, James Johnson2, Brian Johnston2,
Dimitrios Kontoyiannis3, Victor Mulanovich3, Amar Safdar3,
Jeffrey Tarrand3, Roy Chemaly3, Issam Raad3, Herbert DuPont1,4,
Javier Adachi1,3,4. 1The University of Texas Health Science Center
at Houston, Medical School, Houston, Texas, USA; 2The University
of Minnesota, Minneapolis, USA; 3The University of Texas M.D.
Anderson Cancer Center, Houston, Texas, USA; 4The University of
Texas Health Science Center at Houston, School of Public Health,
Houston, Texas, USA
Background: Pyomyositis is an acute bacterial infection of the
skeletal muscle typically caused by Staphylococcus aureus. Few
cases have been described of Escherichia coli pyomyositis and the
associated virulence factors have not been studied.
Objective: To describe the clinical features, the phylogeny and the
virulence factors of E. coli pyomyositis.
Methods: After reviewing the microbiology database and medical
records of all E. coli isolated in our institution (2003–2007), six
cases of E. coli pyomyositis were identified. Clinical characteris-
tics of the disease, laboratory and radiologic findings, treatment
and outcome information were collected. Phylogeny and fifty-one
virulence factors of the isolates were analyzed using PCR.
Results: The mean age was 53 years old with a 1:2 female/male
ratio. All cases had a hematologic malignancy, were receiving
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chemotherapy, and five were severely neutropenic. All had fever
and severe pain over the area involved (4 with calves involve-
ment, 1 with thigh and 1 with axilla). Three were hypotensive
and two required ICU care. Two patients were complicated with
abscess development and two expired, despite adequate therapy
with meropenem and amikacin. MRI findings were compatible with
myositis. All E. coli isolates were resistant to quinolones. Moreover
33% were ESBL positive. Only five isolates were recovered and all
belonged to the B2 phylogenetic group. PCR analysis of these E. coli
showed similar virulence profile, with presence of uidA, adhesins
iha and fimH, toxin sat, siderophores fyuA and iutA, invasins KpsII,
usp, traT, ompT and PAI.
Conclusions: E. coli pyomyositis is an extremely rare clinical man-
ifestation that has emerged as a new problem in our hemato-
logic malignancy patients, and is associated with a high mortal-
ity (33.3%). Our molecular analysis showed that the isolates have
the same phylogenetic background. Moreover, all have similar vir-
ulence factors profile which indicates that these E. coli may have
acquired special properties to be able to invade the muscle. Our
findings provide novel insights into the molecular epidemiology of
invasive extraintestinal E. coli infections. Current studies are on-
going to further characterize this disease and to target the vir-
ulence factors for the potential development of preventive mea-
sures, such as vaccines.
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Using Serum Galactomannan Levels to Guide Early
Anti-fungal Therapy in Haematology Patients at Risk of
Invasive Aspergillosis
Ban Hock Tan, Nidhi Chlebicka, Jenny Guek Hong Low, Gee
Chuan Wong. Infectious Diseases Unit, Department of Internal
Medicine, Singapore General Hospital, Singapore
Background: Patients with prolonged neutropenia are at risk of in-
vasive aspergillosis. Empirical broad-spectrum anti-fungals after 4
7 days of antibiotics have been the standard of care, but might
mean needless treatment in some patients.
Objectives: To determine if serial Galactomannan (GM) monitor-
ing, in the setting of effective anti-candidal prophylaxis, permits
targeted, pre-emptive therapy in those at greatest risk, and spare
febrile patients without evidence of fungal infection other than
prolonged fever from unnecessary and potentially toxic therapy.
Methods: This is a prospective, randomized, non-blinded study
comparing two different strategies. Standard definitions of proven
and probable invasive mold infections were used. Eligible patients
were those with acute leukemias or myelodysplastic syndrome on
induction, re-induction, consolidation or salvage chemotherapy;
patients undergoing bone marrow transplantation; and patients
with severe aplastic anemia on Antithymocyte Globulin. Patients
in the study arm underwent serial GM monitoring and were given
early pre-emptive anti-fungal therapy using an appropriate anti-
fungal agent only if 2 consecutive GM antigen tests were positive
or if they had one positive GM test and a highly suggestive CT tho-
rax. The patients in the control arm were given the standard of
care in accordance with the published guidelines for patients with
febrile neutropenia i.e. no regular GM monitoring, but empirical
antifungals if there was unexplained neutropenic fever after 4-7
days of broad-spectrum antibiotics.
Results: A total of 58 patients were recruited. One hundred and
eighty-six GM tests were performed. The mean number of GM tests
was 2.7 per patient. Duration of neutropenia was 14.4 days in mon-
itoring arm versus 11.4 days in control arm (p=0.133). One patient
in the study arm developed proven IA and one developed prob-
able IA. There was no IA in the control arm. Excluding patients
with probable/proven IA, 7 patients in the monitoring arm and
13 patients in the control arm were started on amphotericin or
voriconazole or caspofungin. There was no difference in the num-
ber of deaths (62.5% vs 37.5%, p= 0.709).
Conclusion: Serial GM monitoring is a simple, non-invasive adjunct
in the management of patients at high risk of IA in the setting of
prolonged febrile neutropenia. Concerns about molds other than
aspergillus limit its usefulness.
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Rothia mucilaginosus, an Uncommon Cause of Bacteremia
in Immunocompromised Patients: Case Report and
Literature Review
Vicki Morrison, Shulasmith Bonham. Veterans Affairs Medical
Center, Minneapolis, MN, USA
Background/Objectives/Methods: We report a case of fatal bac-
teremia caused by Rothia mucilaginosus in a neutropenic patient.
The literature on infections with this pathogen is reviewed.
Results: This 67 yr old male had CLL/SLL, for which he had re-
ceived fludarabine-based therapy. He developed a Richter' s trans-
formation, treated with combination chemotherapy. More recently
he had been diagnosed with hemophagocytic lymphohistiocytosis,
related to possible EBV infection, treated with ganciclovir, IVIG,
dexamethasone, and cyclosporine. He was admitted for febrile
neutropenia, and placed on broad spectrum antimicrobial ther-
apy. Vancomycin was added after coagulase negative staph bac-
teremia was diagnosed. After initial improvement, he developed
fever, diarrhea, myalgias, and fatigue. WBC was <100 cells/mm3,
hgb 10.0 g/dl, and platelet count 20,000. EBV PCR, CMV PCR, and
viral cultures were negative. He was begun on empiric vancomycin,
ceftazidime, and metronidazole. Initial blood cultures revealed
Gram-positive cocci (GPC). He developed hypotension and hypoxia
with continued fevers, with repeat blood cultures (PICC, port, pe-
ripheral blood) growing GPC. Linezolid was added, with concerns
for VRE. The patient deteriorated and died. Stomatococcus mu-
cilaginosus was grown from the initial blood cultures. Rothia mu-
cilaginosus (Micrococcus mucilaginosus, Staphylococcus salivarius,
Stomatococcus mucilaginous) is part of the normal flora of the oral
cavity/upper respiratory tract. This GPC is weakly catalase posi-
tive or negative. Colonies are clear to whitish, mucoid, and adher-
ent to media. This organism has been implicated in cases of bac-
teremia (neutropenic patients), meningitis (pediatric patients with
malignancy, SCT), endocarditis (IV drug user), pneumonia, lung ab-
scess, and peritonitis. Risk factors for infection include immuno-
compromise, neutropenia, mucositis, and broad spectrum antimi-
crobial therapy. By in vitro susceptibility testing, penicillins and
cephalosporins are the treatment of choice.
Conclusion: Rothia mucilaginosus is a relatively uncommon Gram-
positive organism that must also be considered in the differential
diagnosis of bacteremia, meningitis, and respiratory tract infec-
tions in immunocompromised hosts.
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Epidemiology and Mortality of the Multidrug Resistant
Gram-negative Bloodstream Infection in Acute Myeloid
Leukemia
Janaina Midori Goto1, Maria Daniela Di Dea Bergamasco1, James
Farley Maciel2, Maria de Lourdes Chauffaille2, Paola Cappellano1,
Carlos Alberto Pires Pereira1. 1Universidade Federal de São Paulo,
Escola Paulista de Medicina, Infectology Department, Sao Paulo,
Brazil; 2Universidade Federal de São Paulo, Escola Paulista de
Medicina, Hematology Department, Sao Paulo, Brazil
Background: In the last few decades the epidemiology of infections
in neutropenic patient had changed, reflecting prophylaxis and an-
